Jade Biosciences, Inc. · NASDAQ:JBIO
Jade Biosciences — Investor Presentation (October 2024)
29 slides from Jade Biosciences's investor presentation, October 2024
Slide 1: Corporate Presentation October 2024
Corporate Presentation October 2024
Slide 2: Disclaimers
Disclaimers This presentation is for informational purposes only and only a summary of certain information related to Jade Biosciences, Inc. (the “Company”). It does not purport to be complete and does not contain all information that an investor may need to consider in making an investment decision
Slide 3: Developing potentially transformative therapies for high-value Inflammation and Immunology indications
Jade Biosciences is developing potentially transformative therapies for high-value Inflammation and Immunology indications Jade’s mission is to deliver best-in-class therapies for patients living with autoimmune diseases. • Developing potential best-in-class therapies IND- Planned Planned MOA Progra
Slide 4: Experienced Management Team with Backing from Paragon
Experienced Management Team with Backing from Paragon Management Tom Frohlich Andrew King Hetal Kocinsky Valerie Fauvelle CEO CSO, Head of R&D CMO SVP, Regulatory & Quality Jonathan Quick Elizabeth Balta Amy Sullivan Sandy Lewis SVP, Finance GC & Corporate SVP, Development SVP, Biometrics and Secret
Slide 5: JADE-001: a potential best-in-class anti-APRIL mAb for IgAN
JADE-001: a potential best-in-class anti-APRIL mAb for IgAN 5
Slide 6: Potential best-in-class anti-APRIL mAb designed to have disease-modifying MoA in IgAN
Jade is developing a potential best-in-class anti-APRIL mAb designed to have disease-modifying MoA in IgAN Estimated $10B+ newly Anti-APRIL mechanism JADE-001 has potential Efficient development branded market is potentially disease- best-in-class profile path to PoC and market modifying Current app
Slide 7: ~169K+ IgAN patients in US, representing potential $10B+ market
~169K+ IgAN patients in US, majority with persistent proteinuria, representing potential $10B+ market ~1M+ global patients, IgAN patients with persistent proteinuria are at risk of kidney failure significant potential ex-US market potential • IgAN is an autoimmune kidney disease, typically diagnosed
Slide 8: Current IgAN treatments leave significant unmet need, with no disease-modifying approved therapeutics
Current IgAN treatments leave significant unmet need, with no disease- modifying (i.e., long-term GFR-stabilizing) approved therapeutics Systemic Ideal IgAN ACEi / ARB SGLT2i Filspari Tarpeyo Fabhalta glucocorticoids therapy Renin-angiotensin General Dual endothelin / GI-released systemic Complement
Slide 9: Proposed updates to KDIGO guidelines highlight the need for therapies like JADE-001
Proposed updates to KDIGO guidelines highlight the need for therapies like JADE-001, which may reduce pathogenic IgA Proposed guidelines expected to increase IgAN diagnosis … and further underscore the importance of reducing and redefine treatment goals… pathogenic IgA in the treatment paradigm • Re
Slide 10: Reducing pathogenic IgA production by plasma cells is a potentially disease-modifying approach
Reducing pathogenic IgA production by plasma cells is a potentially disease-modifying approach for IgAN Broad B-cell depletion …while targeted plasma cell is ineffective in IgAN… modulation is highly effective. • B-cell depletion with rituximab (anti-CD20) failed to reduce Gd- • APRIL and dual APRIL
Slide 11: Selectively targeting APRIL provides disease modification without BAFF inhibition immunosuppression
Selectively targeting APRIL potentially provides disease modification without added immunosuppression of BAFF inhibition APRIL is the B cell survival factor critically linked Targeting APRIL selectively modulates plasma to IgAN pathogenesis and disease activity cells, maintaining pool of mature B ce
Slide 12: Reductions in proteinuria and IgA indicate APRIL inhibition drives TACI-Fc efficacy
Reductions in proteinuria and IgA in IgAN clinical studies indicate APRIL inhibition is the driving force behind TACI-Fc efficacy 10 0 Weeks Δ from Baseline (%) 0 4 8 12 16 20 24 28 32 36 40 44 48 52 -10 Blisibimod (anti-BAFF) 24h UPCR -20 Sibeprenlimab (anti-APRIL, 8 mg/kg) -30 Sibeprenlimab (anti-
Slide 13: Anti-APRILs show disease modification matching or beating TACIs, with reduced immune suppression
Anti-APRILs have shown evidence of disease modification and clinical activity that matches or beats TACIs, with reduced immune suppression Sibeprenlimab Zigakibart Atacicept Povetacicept “The goal is to reduce pathogenic IgA and get the disease under MoA anti-APRIL anti-APRIL TACI-Fc Engineered TACI
Slide 14: BAFF inhibition is accompanied by potential for significant long-term B cell depletion
BAFF inhibition is accompanied by the potential for significant long- term B cell depletion Long-term BAFF inhibition significantly depletes all B cell … whereas chronic APRIL inhibition does not impact populations… circulating lymphocytes • ~7-year data from belimumab in SLE shows continuous BAFF i
Slide 15: JADE-001 is a potential best-in-class anti-APRIL
JADE-001 is a potential best-in-class anti-APRIL Blocks APRIL with greater potency than clinical benchmarks • Validated mechanism of action • Binds APRIL to neutralize activity • Greater binding affinity than sibeprenlimab (≥5x) and zigakibart (≥14x) Half-life extension through validated YTE Fc modi
Slide 16: Jade mAbs employ proven half-life extension (HLE) technology
Jade mAbs employ proven half-life extension (HLE) technology • Jade mAbs designed to be recycled back into circulation more readily • Drug exists at much higher levels for longer duration of effect pH 5.5 pH 7 • Fewer injections decrease patient burden and can improve compliance and penetration 1st
Slide 17: JADE-001's goal is to introduce Q8W+ dosing for IgAN patients via HLE
JADE-001’s goal is to introduce Q8W+ dosing for IgAN patients via HLE Prior experience, including with Paragon-generated mAbs, indicates HLE could significantly improve dosing over anti-APRILs in development Est. Dosing Human t1/2 (days) Interval • JADE-001 employs well- JADE-001 TPP Targeting estab
Slide 18: JADE-001 HLE strategy and profile in NHPs shows promise with early clone
JADE-001 HLE strategy and profile in NHPs shows promise with early clone* … which is accompanied by prolonged IgA reduction in ~3X increased half-life over sibeprenlimab in NHPs… NHPs following a single, saturating dose PHARMACOKINETICS PHARMACODYNAMICS Note: *Data shown is from an initial clone. A
Slide 19: Deeper APRIL suppression could drive superior efficacy
Deeper APRIL suppression could drive superior efficacy • The highest rates of clinical remission (<0.3 g/day 26 urinary protein excretion) for sibeprenlimab were Placebo 4 mg/kg accompanied by the deepest levels of APRIL 2 mg/kg 8 mg/kg suppression. 12 7 • Safety profile was consistent across dose l
Slide 20: Sibeprenlimab is potentially under-dosed in ongoing Phase 3 trial
Sibeprenlimab is potentially under-dosed in ongoing Phase 3 trial • Sibeprenlimab is being dosed as a single 400mg SC injection Q4W in ongoing global Phase 3 Placebo 2 mg/kg IV 4 mg/kg IV 8 mg/kg IV VISIONARY trial. Annualized eGFR slope • 400 mg SC Q4W is equivalent to ~3.5 mg/kg IV (mL/min/1.73m2,
Slide 21: Potential path to early clinical proof-of-concept and accelerated approval
Potential path to early clinical proof-of-concept and accelerated approval Potential Healthy MOA Program Discovery Phase 1 Initiation Potential Indications Volunteer Data anti-APRIL JADE-001 Ongoing 2H25 1H26 IgAN • NHP and Phase 1 PK/PD could provide early signals of clinical activity; IgA reductio
Slide 22: IgA reduction in healthy volunteers is the critical inflection point for clinical development in IgAN
IgA reduction in healthy volunteers is the critical inflection point for clinical development in IgAN IgA reduction in HVs has been observed to be highly …and IgA reduction was observed to correlate with W36 correlated with IgA reduction in IgAN patients UPCR reduction, the endpoint for accelerated
Slide 23: Potential of JADE-001 in IgAN
Potential of JADE-001 in IgAN Potential best-in- Potential Disease- More convenient class clinical modifying MoA dosing activity Potential to deplete pathogenic Enabled by half-life extension Designed for superior potency IgA and avoids broad B-cell technology and half-life with potential to inhibit
Slide 24: Pipeline opportunities beyond IgAN
Pipeline opportunities beyond IgAN 24
Slide 25: Additional Jade pipeline programs are expected to focus on best-in-class profiles in high-value I&I indications
Additional Jade pipeline programs are expected to focus on best-in- class product profiles in high-value I&I indications I&I indications Potential Best-in- Potential Rapid Expected minimal Jade team with significant class and best- path to clinical competition expertise market in-indication PoC oppo
Slide 26: Jade Biosciences is developing transformative therapies for high-value I&I indications
Jade Biosciences is developing transformative therapies for high- value I&I indications • Approximately $300 million raised to date, including anticipated proceeds from an oversubscribed pre- closing private financing, from syndicate of top tier Planned Planned healthcare investors, including: MOA P
Slide 27: Estimated capitalization following close of transactions with Aerovate and pre-closing private placement
Estimated capitalization following close of transactions with Aerovate and pre-closing private placement Shares on an as- Expected ownership of the converted basis combined company Aerovate • Shares of common stock outstanding 28,867,711 1.6% • Shares of common stock outstanding 202,760,666 (includi
Slide 28: Thank you
Thank you 28
Slide 29: JADE-001 HLE strategy and profile in NHPs shows promise
JADE-001 HLE strategy and profile in NHPs shows promise* … which is accompanied by prolonged IgA reduction in ~3X increased half-life over sibeprenlimab in NHPs… NHPs following a single, saturating dose PHARMACOKINETICS PHARMACODYNAMICS Note: *Data shown is from an initial clone. A development candi
Jade Biosciences — Investor Presentation (October 2024) on 6ix